My Prayer for You May God FILL Your •FAMILY with unity and joy, •FRIENDS with loyalty and trust, •HEART with love and peace, •SOUL with praise and thanksgiving. •MIND with wisdom and discernment, •BODY with vibrant health, •DAYS with wonderful memories, •LIFE with PURPOSE
Sitting on the wings of a butterfly... looking over the horizon. Waiting for news to take action... In the meantime, my butterfly gently glide with glee, manoeuvring this landscape full of plants and animals.
Announcement Description RESEARCH PROTOCOL ON THE EFFECTIVENESS OF ORAL POLIO VACCINE (OPV) AS A PREVENTIVE PROTECTION AGAINST THE SARS-COV-2 VIRUS The Board of Directors of Ho Wah Genting Berhad wishes to announce that its wholly owned subsidiary, HWGB Biotech Sdn Bhd (Formerly known as HWG Consortium Sdn Bhd) (“HWGB Biotech”), had on 7 September 2020 submitted a research protocol (with Research ID 56372) to National Medical Research Register (“NMRR”) under The Ministry of Health, Malaysia (“MOH”) to evaluate the effectiveness of OPV as a preventive protection against the SARS-CoV-2 virus (“Research Protocol”). The Research Protocol will be fully funded by HWGB Biotech who will hold the full rights on the clinical trial and other related matters.
Please refer to the attach file for the details of the announcement. This announcement is dated 7 September 2020.
COUNT OUR BLESSINGS ONE BY ONE Our FAMILY is our true everlasting love. Our FRIENDS are precious jewels. Our HEALTH is our wealth. Our EXISTENCE is a priceless gift. BE GRATEFUL AND NEVER FORGET HOW BLESSED WE ARE
XINKEXIAN (BEIJING) BIOTECHNOLOGY - Partnerships for Global Vaccine Development - Meningitis Vaccine Project (MVP) for Sub Saharan Africa - Partnerships for Global Vaccine Development Rotavirus Vaccine
The Board of Director of HWGB wishes to announce that the Company had on 21 May 2020 received a letter dated 20 March 2020 from Sabah Chief Minister’s Department informing that approval has been given to HWGB to bring in Covid-19 test kit to Sabah for the purpose of Covid-19 screening.
As at the date of the announcement, HWGB is the authorised distributor of Covid-19 diagnosis kit manufactured by Shanghai Liangrun Biomedicine Technology Co Ltd, Wuhan Easydiagnosis Biomedicine Co. Ltd. and Xiamen AmonMed Biotechnology Co. Ltd.
Over the course of the year, HWGB has made a slew of announcements following ventures into the Covid-19 related business that had been announced by the group earlier that range from test kits to clinical trials for vaccines.
1) In May, HWGB said its unit HWG Consortium Sdn Bhd (HWGC) had been appointed the authorised distributor of Shanghai Liangrun Biomedicine Technology Co Ltd for the distribution of its antibody IgM/IgG of novel coronavirus Covid-19 diagnostic kit in Malaysia for a validity period from May 15 to Dec 31.
It said HWGC had also submitted an application to the Ministry of Health (MoH) for the certification of the diagnostic kit, pending approval.
COMMENT - The duration needed to obtain MOH's approval for the test kits averaged about 3 to 4 months. The outcome should be known anytime now.
2) On June 3, the group’s unit HWGB Biotech Sdn Bhd received an authorisation letter from Sansure Biotech Inc to be Sansure’s general distributor to promote and publicise its Covid-19 nucleic acid detection kits and instruments in Malaysia.
3) On June 19, it entered into a product purchase agreement with Zhejiang Plame Medical Technology Co Ltd, a company duly authorised by Shanghai Liangrun to handle matters relating to its diagnostic kit in Malaysia.
4) On June 26, it said its unit HWGB Biotech had entered into a memorandum of understanding (MoU) with Gnosis Laboratories (M) Sdn Bhd.
5) These culminated in its latest filing last Thursday, when HWGB said HWGB Biotech had partnered with US-based E-MO Biology Inc (EBI) for HWGB to invest a sum of US$1 million (RM4.2 million) in EBI, entitling it to 40% of profit from the commercialised vaccine.
HWGB said it will have exclusive rights for the production, distribution and sale of the repurposed vaccine based on the polio vaccine for use in preventing Covid-19 infections in Southeast Asian countries.
“EBI on June 15 submitted the Initial Investigational New Drug application to the United States Food and Drug Administration to conduct phase IV clinical trials for a new indication which proposes the use of the existing poliomyelitis virus vaccine for prevention of Covid-19, which is currently pending approval;
TF AA said 2019 is the best year, results proved otherwise even without covid then. LOL. As for this, really no idea who will choose to partner it and on what ground? Excellent performance in the past? Sound financial status? Strong networking with service providers and relevant authorities? Without other vaccines players in the country? Anyway, price may be pushed up by traders, LT negative at this price unless proven me wrong.
KUALA LUMPUR (Sept 9): Ho Wah Genting Bhd, which has jumped on the COVID-19 bandwagon, is considering appointing Xinkexian (Beijing) Biotechnology Co, Ltd (XKX) as its non-exclusive manufacturer to produce COVID-19 vaccines.
In a filing with Bursa Malaysia today, Ho Wah said its wholly-owned subsidiary HWGB Biotech Sdn Bhd has entered into a Memorandum of Understanding (MoU) with XKX for a possible partnership.
“The MoU aims to appoint XKX as a non-exclusive manufacturer to produce the vaccines upon successful completion of the research and development (R&D) of vaccines, immunological treatment and diagnostic product development in relation to the COVID-19 virus and upon approval from the US Food and Drug Administration,” said Ho Wah.
Based in Anhui province in China, XKX is principally engaged in the R&D of preventive vaccines for human use, manufacture, marketing and sales agent of preventive vaccine.
The group said the MoU is not expected to have any material effect on its earnings, net assets, gearing, share capital and substantial shareholders’ shareholding for the financial year ending Dec 31, 2020.
“Should the business materialise, it is expected to contribute positively to the future earnings of the group,” said Ho Wah.
Shares of Ho Wah Genting closed 9.5 sen or 11.45% lower at 73.5 sen today, valuing the group at RM383.79 million
Read also:
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Neozy
84 posts
Posted by Neozy > 2020-09-05 13:15 | Report Abuse
paperplane did u remove a message? i saw it that day u said u buy back ~ then it start to go down d the price. so are u losing money for that ?